Welcome to our dedicated page for NMTR news (Ticker: NMTR), a resource for investors and traders seeking the latest updates and insights on NMTR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NMTR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NMTR's position in the market.
9 Meters Biopharma (NASDAQ: NMTR) announced significant clinical advancements and financial results for Q2 2020. The company initiated a Phase 1b/2a trial for a long-acting GLP-1 agonist in short bowel syndrome, with top-line data expected in Q1 2021. They amended the primary endpoint for Phase 3 larazotide trial in celiac disease, reducing participants to 525. However, Q2 net loss increased to $44.6 million from $4.5 million YoY, primarily due to merger-related charges, but cash reserves grew from $2.7 million to $13.5 million.
9 Meters Biopharma (NASDAQ:NMTR) initiated a Phase 1b/2a clinical trial for a proprietary GLP-1 agonist for short bowel syndrome, with first dosing in July and expected top-line data by Q1 2021. They amended the primary endpoint in a Phase 3 trial for larazotide in celiac disease, reducing participants from 630 to 525 while keeping 90% statistical power. Despite the pandemic's challenges, clinical sites increased to 115. The company reported a net loss of $44.6 million for Q2 2020, primarily due to merger-related charges, but its cash position improved to $13.5 million.